Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5Q71U)

Drug Name

N6-(4-hydroxybenzyl)adenine riboside Drug Info

Synonyms

N6-(4-Hydroxybenzyl)-adenosine; 110505-75-4; n6-(4-hydroxybenzyl)adenosine; N6-(4-hydroxybenzyl)adenine riboside; CHEMBL224024; C17H19N5O5; p-Topolin riboside; Adenosine, N-[(4-hydroxyphenyl)methyl]-; SCHEMBL639446; N6-(p-hydroxybenzyl)-adenosine; KS-00001DDJ; CTK0D4708; DTXSID00440568; UGVIXKXYLBAZND-LSCFUAHRSA-N; MolPort-023-332-931; ZINC28638129; BDBM50208945; 1962AA; ANW-64712; AKOS016007097; CS-5067; NCGC00484059-01; HY-18775; AJ-83558; TC-153457; KB-258567; AB3000026; AX8235067

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 10474479
CAS Number: CAS 110505-75-4
TTD Drug ID: DM5Q71U

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adenosine A2a receptor (ADORA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[2]
Istradefylline	DM20VSK	Parkinson disease	8A00.0	Approved	[3]
Regadenoson	DM76VHG	Radionuclide imaging	N.A.	Approved	[4]
Tozadenant	DMATC14	Parkinson disease	8A00.0	Phase 3	[5]
Binodenoson	DMVHF8G	Hypertension	BA00-BA04	Phase 3	[6]
Apadenoson	DMD8QTC	Coronary artery disease	BA80	Phase 3	[7]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[8]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[9]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[10]
BIIB014	DMH7RJ1	Parkinson disease	8A00.0	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A2a receptor (ADORA2A)	TTM2AOE	AA2AR_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Neuroprotective principles from Gastrodia elata. J Nat Prod. 2007 Apr;70(4):571-4.
2	Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5	Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
6	Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
8	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
9	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
10	Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
11	Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.